



(-Translation-)

**Minutes of the 2022 Annual General Meeting of Shareholders
Bangkok Dusit Medical Services Public Company Limited (the “Company”)**

Date, time, and venue:

The Meeting was held on 12 April 2022, at 13:30, at His Royal Highness Crown Prince Maha Vajiralongkorn Ballroom, 3rd Floor, Royal Golden Jubilee Building, Soi Soonvijai (Soi Petchburi 47), New Petchburi Road, Huai Khwang District, Bangkok.

Directors in attendance:

1. Professor Emeritus Santasiri Sornmani, M.D. Chairman of the Board of Directors
2. Mr. Chuladej Yossundharakul, M.D. Vice Chairman of the Board of Directors / Member of Executive Committee / Member of the Nomination and Remuneration Committee
3. Mr. Prasert Prasarttong-Osoth, M.D. Director and Founder
4. Miss Poramaporn Prasarttong-Osoth, M.D. President and Chairperson of the Executive Committee
5. Mrs. Narumol Noi-am Director / Member of the Executive Committee / Member of the Risk Management Committee / Senior Executive Vice President and Chief Financial Officer
6. Mr. Weerawong Chittmittrapap Independent Director / Chairman of the Corporate Governance Committee and Member of the Audit Committee
7. Mr. Chavalit Sethameteekul Independent Director / Chairman of the Audit Committee and Member of the Nomination and Remuneration Committee
8. Mr. Predee Daochai Independent Director and Chairman of the Nomination and Remuneration Committee
9. Mr. Sripop Sarasas Director / Member of the Risk Management Committee / Member of the Corporate Governance Committee and Chief Administrative Officer

10. Mr. Kan Trakulhoon	Independent Director
11. Mr. Thongchai Jira-alongkorn	Director and Member of the Executive Committee
12. Mr. Att Thongtang	Director
13. Mr. Puttipong Prasarttong-Osoth	Director
14. Mr. Chairat Panthuraamphorn, M.D.	Director / Member of the Executive Committee and Chief Operating Officer
15. Mr. Subhak Siwaraksa, Ph.D.	Independent Director and Member of the Risk Management Committee
16. Mr. Veerathai Santiprabhob, Ph.D.	Independent Director and Member of the Audit Committee

Directors attending the meeting via electronic means:

1. Mr. Pradit Theekakul	Director / Chairman of the Risk Management Committee and Member of the Corporate Governance Committee
-------------------------	---

Directors absent:

1. Mr. Arsa Sarasin	Independent Director (on a mission)
---------------------	-------------------------------------

There were 17 directors attending the Meeting, out of a total of 18 directors, representing 94.44% of the total number of directors.

Attendees:

1. Ms. Kessara Wongsekate	Vice President and Company Secretary
2. Mrs. Wannapa Pavavech	Assistant Chief Financial Officer, Accounting
3. Ms. Ajaya Intaraprasong	Assistant Vice President, Investor Relations
4. Ms. Siripat Phaisuwat, Ph.D.	Assistant Innovation Director

Auditors from EY Office Limited:

1. Mr. Wichart Lokatekrawee	Partner
2. Mr. Samran Taengcham	Partner

Legal advisor from Weerawong, Chinnavat & Partners Ltd.:

1. Miss Pratumporn Somboonpoonpol	Senior Associate
-----------------------------------	------------------

Preliminary proceedings:

Miss Kessara Wongsekate, the Company Secretary, informed the Meeting that there were 1,831 shareholders attending the Meeting in person and by proxy, representing 11,106,913,669 ordinary shares, equivalent to 69.89% of the total number of paid-up and issued shares. A quorum was thus constituted in accordance with Article 33 of the Articles of Association of the Company, which provides that, at a shareholders' meeting, unless otherwise prescribed by law, the presence of no fewer than 25 shareholders and/or proxies appointed by shareholders that hold shares amounting to no less than one-third of the total number of sold shares in aggregate, is required to constitute a quorum.

Professor Emeritus Santasiri Sornmani, M.D., the Chairman of the Board of Directors, who presided as the Chairman of the Meeting (the "**Chairman**"), declared the 2022 Annual General Meeting of Shareholders duly convened and introduced the directors, executives of the Company, and external attendees, who were representatives of the auditor and the legal advisor of the Company. The Chairman then delegated Miss Kessara Wongsekate, the Company Secretary, to inform the Meeting of the procedures for casting votes, as follows:

Miss Kessara Wongsekate, the Company Secretary, explained that, to ensure that the Meeting complied with the principles of good corporate governance, for the voting part of the Meeting, the Company would explain the procedures for voting and the counting of votes, as set out below.

- 1) With regard to voting in the Meeting, a shareholder will have a number of votes equivalent to the number of shares he/she/it holds in the Company, whereby one share is equivalent to one vote.
- 2) In the interests of expediting the process for each agenda item, with respect to voting in each agenda item, the Company will ask if any shareholder/representative wishes to vote 'against' or to abstain from voting, and request such shareholder/representative to mark under 'against' or 'abstain' on his/her ballot card and raise his/her hand to signal to the staff to collect the relevant ballot card for the purpose of vote counting. In vote counting, the Company will deduct both the votes cast against or in abstention of an agenda item from the total number of votes, and the remaining number will be treated as the total number of votes of approval for that agenda item.

Agenda Item 4 deals with the appointment of directors in replacement of the directors who are due to retire by rotation. To be in compliance with the best practices in convening shareholders' meetings, the voting on this agenda item will be carried out on an individual basis. With regard to the counting of votes for the election of each director, the Company will deduct the number of ballots with a vote cast against or in abstention from the total number of votes. The remaining votes shall be considered as the total number of votes in favor of this agenda item. For the purpose of transparency, the Company shall collect all ballot cards after the vote casting on the appointment of the last director. In the interest of convenience and expediency, the Company's staff will collect the ballot cards from the shareholders attending the Meeting.

- 3) A ballot that is filled in with more than one mark in the space provided; or a ballot that casts a vote expressing a conflict of intent; or a ballot with a vote that has been crossed out without a signature thereon; or a ballot on which there are votes cast in excess of the permitted number of votes on a ballot, shall be considered invalid.

If a shareholder wishes to correct his/her vote on the voting ballot, the shareholder should cross out the existing vote on the voting ballot and affix his/her signature thereto. Any vote cast in a different manner from that which is specified above shall be considered void.

- 4) A shareholder or a proxy who wishes to leave the Meeting before the Meeting is adjourned is requested to submit his/her voting ballot to the staff, in advance, before he/she leaves the meeting room. The Company will deduct the number of shares of such a shareholder, attending the Meeting in person or by proxy, from the quorum.
- 5) To minimize the risk in relation to Coronavirus 2019 (COVID-19), the Company asks shareholders to wear masks at all times throughout the Meeting, and the Company did not prepare microphones for shareholders to ask questions. A shareholder who would like to ask a question is required to write it on the paper provided, specifying his/her first and last name and indicating whether he/she is a shareholder or a proxy, and send it to the Company's staff for it to be passed to the Chairman. If there is a question in respect of an agenda item of the Meeting and concerning the Company's operations which is not responded to during the Meeting, the Company will record the question, the answer, and the name of the person who asked the question, in the minutes of the Meeting.

To ensure that the Meeting was conducted in compliance with good corporate governance principles, the Company delegated Miss Thanapan Pachimsawat, a legal advisor from Weerawong, Chinnavat & Partners Limited, to act as the voting inspector.

The Chairman then informed the Meeting that, in preparation for this 2022 Annual General Meeting of Shareholders, from 1 December 2021 to 14 January 2022, the Company gave the shareholders the opportunity to propose matters that would be beneficial and appropriate as agenda items in advance of this Meeting, as well as to nominate a person who is knowledgeable, competent, and qualified for appointment as a director. The guidelines for proposing such additional matters were posted on the Company's website. By the end of the given period, no shareholder had proposed any matter in advance for the Board of Directors to consider and add to the list of agenda items for this Meeting, and there was no nomination of other qualified persons for appointment as directors. Thereafter, the Chairman proceeded with the Meeting in accordance with the following agenda items.

Agenda Item 1: To acknowledge the Company's 2021 performance

The Chairman assigned Miss Poramaporn Prasarttong-Osoth, M.D., the President, to inform the Meeting of the Company's performance during the year 2021.

Miss Poramaporn Prasarttong-Osoth, M.D., the President, presented to the Meeting an overview of the performance of the Company during the year 2021. The important details are summarized as follows:

Overview of the Company

- Presently, the Company has a hospital business with a total of 53 hospitals in its network, and with a total of approximately 8,200 hospital beds. There are approximately 11,000 doctors and 7,000 nurses. Furthermore, the Company has established 11 Centers of Excellence in the Company's network hospitals in each region, including the Kingdom of Cambodia.

- In the year 2021, TRIS Rating affirmed the Company rating at “AA” with a “Stable” outlook. In addition, the Company has been selected as a member of the Dow Jones Sustainability Indices (DJSI) -Emerging Markets for 2021, as well as chosen to be in the list of Thailand Sustainability Investment (THSI) in the service sector for the year 2021, which is the second consecutive year, by the Stock Exchange of Thailand.
- The Company’s network hospitals consist of Bangkok Hospital group, Samitivej Hospital group, Phyathai Hospital group, Paolo Hospital group, BNH Hospital, and Royal Hospital group, which are hospitals in the Kingdom of Cambodia.
- The Company also operates other non-hospital businesses, which are BDMS Wellness Clinic, A.N.B. Laboratories Co., Ltd. (a manufacturer and distributor of saline solution), The Medicpharma Co., Ltd. (a drug manufacturer and distributor), and Save Drug pharmacy.

Collaboration in the midst of the COVID-19 Disease outbreak

- In 2021, the Company collaborated with the government and the private sector in treating and preventing the spread of COVID-19 by vaccinating people more than 4,000,000 doses of the vaccine provided by the government and the private sector. The Company was able to conduct an RT-PCR and ATK test for COVID-19 over 10,000 times a day. Additionally, there were alternative hospitals (Hospitels), for which the Company provides services with various hotels to supply approximately 6,000 beds, and there were approximately 2,300 beds to treat COVID-19 patients in hospitals (Cohort Wards).
- In partnership with the Vejdusit Foundation and the Royal Thai Air Force, the Company established the BDMS field hospital, the Royal Thai Air Force Stadium (Thupatemi) to provide treatment for covid-19 patients in the yellow level. When the situation has been handled, the aforementioned field hospital and medical equipment were handed over to the Royal Thai Air Force in October 2021 for continued use in caring for the people.

Operating strategy

- The Company prioritizes service recipients in all groups with a policy of setting reasonable prices (Value-based pricing) as well as strengthens relationships with and provides services to various insurance companies, the National Health Security Office (NHSO), and the Comptroller General’s Department.
- The Company develops innovations to provide “Smart Healthcare” by integrating technology and innovation as an important part to enhance medical services (Digital Health), doing marketing through digital media or electronic devices (Digital Marketing), and developing software applications to facilitate the use of mobile devices (Mobile Applications) in connection with healthcare services, as well as modernizing various hospital systems.
- The Company emphasizes a medical strategy, focusing on its leading hospitals as Centers of Excellence. The BDMS Genomic Center has been established with the objective of developing a comprehensive individual genetic testing. In addition, there is a co-management of the Company’s procurement system among all the network hospitals. All of these has been accomplished by cooperation of doctors, nurses, and support teams, as well as by managing all of the medical devices for maximum benefit.

- The Company focuses on operating strategies for sustainable development that take into account the environment, society, and good governance.

Investment in hospital expansion and development

- In 2022, the Company plans to invest in increasing the number of beds in the Bangkok Hospital Udon Thani by 142 beds, and Paolo Chokchai 4 Hospital, in the premium patient segment by 59 beds, and social security by 30 beds.
- At the end of 2022, the Company plans to open the Bangkok Rayong Cancer Hospital, which is a specialized hospital for treating cancer patients, and located in the vicinity of Bangkok Hospital Rayong.
- In 2023, the Company will have additional 160 beds from Phyathai 1 Hospital and 100 beds for Social Security Patients from Phyathai Sriracha Hospital.
- In 2024, the Company will have additional 102 beds from Samitivej International Children's Hospital.
- In 2025, the Company plans to increase 200 beds in the Eastern Special Development Zone project at Bangkok Hospital Rayong - Pluak Daeng, as well as to expand the area of the existing hospitals.
- The Company focuses on developing major hospitals as Centers of Excellence by concentrating on a treatment of trauma patients, considering that accidents are the leading cause of death and disability among Thai people. The Center of Excellence also focuses on orthopedics, neurosciences, heart, and cancer.

Innovation

- The Company collaborated with The Siam Cement Public Company Limited in developing the existing equipment to respond to service users' needs and reduce imports from overseas, as follows:
 - Production of Containers for Disposal of Sharp Equipment: manufactured in Thailand and designed by in-house personnel, by means of placing syringes in the containers horizontally to conserve space. They are currently being employed throughout the hospitals in the BDMS network and other healthcare operators.
 - Production of Transfer Wheelchairs, which was co-designed by The Siam Cement Public Company Limited and the BDMS staff who regularly uses wheelchairs in their work, in response to issues encountered while transferring patients within the hospital in order to make the process safer and more comfortable. Also, these wheelchairs can be manufactured domestically, which gives them a pricing advantage and enhances the country's future competitiveness. The Company has already utilized the wheelchairs in network hospitals.
 - Medication Carts, which will function with the Company's information technology system to improve the safety of medications being distributed to hospital patients.

- The Company developed a digital service model through the development of a Telehealth platform that supports the use of mobile devices (Mobile Application) as follows:
 - My B+ Application for customers who use the services of Bangkok Hospital group.
 - Samitivej Plus for customers who use the services of Samitivej Hospital group.
 - Health Up for customers who use the services of Phyathai Hospital and Paolo Hospital group.
- The Company has joint investments with Thai start-ups companies in many disciplines for Thai healthcare, which most of the products are still in the early stages of development. For products already in use, it includes the use of artificial intelligence in radiology.

BDMS Genomic Center

- The Company jointly invested with NovogeneAIT Genomics Singapore Pte. Ltd. to establish the BDMS Genomic Center, Thailand's first center that offers in-depth genetic analysis to develop the capacity for individualized medical care in terms of preventive and treatment planning in a timely manner, with plans to open for service in the second quarter of 2022.

BDMS Health Ecosystems

- The Company learned from its experience with the COVID-19 pandemic that healthcare cannot be limited to hospitals alone. The Company needed to develop comprehensive healthcare by caring for people of all ages and in all places in order to promote convenience and confidence in the quality of service. The Company has developed the BDMS Health Ecosystem project, which consists of medical consultation via mobile devices (Tele-consultation), a medication delivery service (Tele-pharmacy), Home lab service, and Home Care. Furthermore, it also provides healthcare services as a network through a collaboration with network laboratories and drug stores. The BDMS Health Ecosystems also includes patient health records, health packages, health content, and health-related product distribution (Health Mall).

Sustainability action plan

The Company implements plans in accordance with its framework for sustainable development, which consists of the following key points:

- **More than excellence**, which means establishing an effective cybersecurity system and user data to deliver digital services to users and develop a sustainability evaluation of the Company based on key issues.
- **Create holistic innovation**, which means supporting a corporate innovation culture and recruiting partners to develop health innovation.
- **Create sustainable participation**, which means adapting procedures and reviewing environmental data gathering in accordance with international standards to support strategies to mitigate the effects of global warming, as well as establishing criteria for human rights compliance.

- **Contribute value to society**, which means improving health literacy and community and social life saving fundamentals for well-being.

The Company's past performance resulted in the Company being selected in the Dow Jones Sustainability Indices (DJSI) in the Emerging Markets Group of the year 2021, a noteworthy achievement in the national and worldwide sustainability arena. BDMS is the first healthcare group in Thailand, and in Asia, to be chosen for this honor.

Sustainability activities succeeded in 2021

- The Company organized “the Resiliency of Wastewater Treatment project” at Bangkok Hospital Phuket as a method for treating wastewater to accommodate the increased number of service recipients during the COVID-19 Disease outbreak and to manage resources effectively without affecting the community's ecosystem surrounding the hospital, which the said project was a winning project in the Earth Healthcare category of the BDMS Awards in 2021.
- The Company organized “the Kla Dee Phithak Jai project” by Bangkok Hospital Hat Yai, a workshop project to provide knowledge and skills in resuscitation and first aid to the communities surrounding the hospital. This resulted in private sector project participants were able to safely treat a patient in their location. The project, along with other projects, resulted in the Company being included in the Dow Jones Sustainability Indices (DJSI) - Emerging Markets for 2021.

In commemoration of the Company's 50th anniversary in 2022, the Company created a BDMS 50-year resuscitation training program. It is a training course on proper basic life support by 53 hospitals in each area of the Company's network in Thailand, with the purpose of arranging this project being that “There can be more than one hero in this world; BDMS joins together to build a secure Thai society”.

Awards

- The Company received the following Global Health and Travel Awards 2021, organized by Global Health and Travel magazine:
 - BDMS Wellness Clinic won the following three awards:
 - 1) Integrated Health and Wellness Service Provider of the Year in Asia-Pacific;
 - 2) Dental Medical Centre of the Year in the Asia-Pacific; and
 - 3) Fertility Medical Centre of the Year in the Asia-Pacific.
 - Samitivej Hospital won the following five awards:
 - 1) Smart Hospital of the Year in the Asia-Pacific;
 - 2) Best Hospital of the Year in Thailand;
 - 3) Hospital COVID-19 Healthcare Service Provider of the Year in the Asia-Pacific;
 - 4) Pediatric Cardiology Service Provider of the Year in Asia-Pacific; and
 - 5) Gastroenterology Service Provider of the Year in the Asia-Pacific.

- Bangkok Phuket Hospital won the award of “Heart and Vascular Service Provider of the Year in the Asia-Pacific”.
- The award of All-Asia Executive Team 2021 – Most Honored Company – Thailand in the categories of Best CEO, Best CFO, Best IR Professional, Best IR Program, and Best ESG in the Healthcare & Pharmaceutical Sector for the rest of Asia (ex-China) for the year 2021 from Institutional Investor Magazine.
- The award of “Most Outstanding Company in Thailand – Healthcare Sector” by Asiamoney Magazine.
- The award of “Outstanding Investor Relations Awards” for listed companies with a market capitalization of more than THB 100,000 million in the SET Awards 2021, organized by the Stock Exchange of Thailand.
- The award of “Best IR in the Healthcare Sector” from IR Magazine.

The Chairman then gave the shareholders an opportunity to ask questions or express opinions with respect to this agenda item.

Mr. Wanchai Lertsrichatuporn, a proxy, asked the Company the following questions:

1. Recently, numerous prominent hospitals in Thailand have partnered with one another to enter the wellness business. Therefore, what is the Company’s perspective on this situation?
2. Will the recent restoration of diplomatic relations between the Kingdom of Saudi Arabia and Thailand create prospects for services to Saudi Arabian clients?

Miss Poramaporn Prasarttong-Osoth, M.D., the President, answered as follows:

1. The Company has operated in the wellness business for approximately ten years, starting with a wellness clinic within a hospital, which was eventually separated from the hospital around three years ago. The Company can be regarded as a healthcare leader in the wellness business, with close supervision by doctors, nurses, and healthcare professionals. Despite that currently, there are business groups, both hospitals and non-hospitals, interested and participating in the wellness business, the Company is confident that with the Company’s experts and knowledge from both domestic and foreign sources, it will be able to develop and grow such business in the future.
2. In the past, the Company had patients from the Kingdom of Saudi Arabia, the number of which dropped later. However, the Company is currently seeing an increase in patients from the Kingdom of Saudi Arabia.

Mr. Wasan Pongputhamon, a shareholder, asked the Company the following questions:

1. How is the BDMS Wellness Clinic progressing and performing?
2. How has the cooperation been with the health insurance industry?
3. How has the Company altered its business strategy as a result of the COVID-19 pandemic?

Miss Poramaporn Prasarttong-Osoth, M.D., the President, answered as follows:

1. At present, the Company does not separate the operating results of the BDMS Wellness Clinic from its other operating results.
2. The Company cooperates well with most of the health insurance companies, both in Thailand and overseas. The percentage of patients covered by health insurance has increased from approximately 20% to 30%, and a variety of insurances, both general and disease-specific, have been launched.
3. Due to changing situations, the Company needs to adjust itself and mitigate the impacts through various forms of healthcare, both inside and outside the hospital, in order to increase the convenience and accessibility of services in the future. The most critical aspect is to uphold the Company's medical standards.

Mrs. Kamolvijit Bhoparipat, a proxy, inquired as follows:

1. Which countries make up the Company's overseas clientele, which accounts for 18% of its business? Also, what is the ratio of clients from each country.
2. How interested is the Company in obtaining clients from China via agents, branches, or country partners?

Mrs. Narumol Noi-am, Senior Executive Vice President and Chief Financial Officer, answered as follows:

1. Currently, the ratio of Thai patients is approximately 82% and that of foreign patients is approximately 18%, based on service income. The patients in 5 main countries include, Japan, Cambodia, the United States of America, the United Kingdom, and France, most of which are foreigners living in Thailand (EXPAT) while fly-in patients are still a modest number.
2. For the Chinese market, the Company has collaboration with business alliances in China such as huge insurance companies, PingAn Health, and Ping An Good Doctor.

In the absence of further questions and opinions, the Chairman then asked the Meeting to acknowledge the Company's 2021 performance.

Resolution: The Meeting acknowledged the Company's 2021 performance.

Agenda Item 2: **To consider approving the Company and its subsidiaries' audited consolidated financial statements for 2021**

The Chairman proposed that the Meeting consider and approve the financial statements for the year ended 31 December 2021, as detailed in the Financial Statements and the Auditor's Report in Form 56-1 One Report, as delivered to the shareholders together with the notice of the Meeting, and asked Mr. Chavalit Sethameteekul, the Chairman of the Audit Committee, to explain the information in support of the Meeting's consideration.

Mr. Chavalit Sethameteekul, the Chairman of the Audit Committee, informed the Meeting that the Audit Committee had considered the information in the Auditor's Report and the Financial Statements for the year ended 31 December 2021, which had been audited by Mr. Wichart Lokatekrawee, the Company's certified public accountant from EY Office Limited, and was of the view that the Financial Statements had been prepared in accordance with accounting standards and reflected accurate

information by disclosing sufficient material facts. The auditor was also of the view that the financial statements accurately represented the Company's financial position, operating results, and cash flow, in accordance with financial reporting standards. Also, the Audit Committee was of the view that the related party transactions that occurred in the year 2021 and that appear in Form 56-1 One Report were reasonable and had been entered into on an arm's length basis. A summary of the income statement and statement of financial position as at the end of the year 2021 is as follows:

Summary of the 2021 Income Statement

(Unit: THB million)	Consolidated Financial Statements		Change
	2021	2020	
Operating income	75,714	69,057	9.6%
Total revenues	75,719	71,492	5.9%
Cost of hospital operations and goods sold	49,462	46,371	6.7%
Administrative expenses	15,029	14,161	6.1%
Profit for the years	8,490	7,649	11.0%
Net profit attributable to the Company's shareholders	7,936	7,214	10.0%

Summary of the Statement of Financial Position as at 31 December 2021

(Unit: THB million)	Consolidated Financial Statements		Change
	2021	2020	
Cash and cash equivalents	10,934	19,666	(44.4%)
Trade and other receivables	9,131	7,192	27.0%
Property, premises, and equipment	79,689	81,313	(2.0%)
Total assets	128,454	136,050	(5.6%)
Total liabilities	40,689	44,588	(8.7%)
Total shareholders' equity	87,765	91,463	(4.0%)
Total liabilities and shareholders' equity	128,454	136,050	(5.6%)

Management Discussion and Analysis

- Operating income in 2021 increased by 10% from 2020 as a result of:
 - Income from Thai patients increasing by 14%.
 - Income related to an increase in the number of COVID-19 patients.
 - Income from foreign patients decreased by 6% due to travel restrictions.
- Costs increased by 7% from 2020, which was an increase at a lower rate than the increase in operating income as a result of the continuous cost control.

- The Company recorded a net profit of THB 7,936 million, resulting from revenue growth, cost control, and a reduction in financial costs.

The Chairman then gave the shareholders an opportunity to ask questions and express opinions related to this agenda item.

Mr. Sathaporn Pungnirun, a shareholder, asked questions as follows:

1. The Return on Assets (**ROA**) ratio and the Return on Equity ratio (**ROE**) in 2021 decreased when compared to the year 2019. How will the Company proceed to improve these ratios?
2. Will the Company's net profit return to normal, or be better than in 2019? If so, how?

Mrs. Narumol Noi-am, the Senior Executive Vice President and Chief Financial Officer, replied as follows:

1. In 2019, the ROA and ROE ratios were high because the Company had a special transaction of selling shares in Ramkhamhaeng Hospital Public Company Limited. The ratios in the years 2020 and 2021 are considered as normal for the Company.
2. Considering the Company's current operating results, it can be seen that the Company's income has increased. The Company initially forecasts that it will take approximately one year after the service recipients from abroad return, whereby the amount of the Company's operating results will be at a level similar to the amount before the COVID-19 pandemic.

No shareholders asked any further questions or expressed any further opinions. Therefore, the Chairman requested the Meeting to vote on this agenda item. Miss Kessara Wongsekate, the Company Secretary, informed the Meeting that the resolution on this agenda item shall be passed by a majority vote of the shareholders attending the Meeting and casting their votes.

Resolution: After due consideration, the Meeting resolved, by a majority vote of the shareholders attending the Meeting and casting their votes, to approve the financial statements for the year 2021, in accordance with the following votes:

	Number of votes	Percentage
Approved	11,235,513,700 votes	99.80%
Disapproved	23,037,859 votes	0.20%
Abstained	1,220,300 votes	-
Invalid ballots	0 votes	-

Agenda Item 3: To consider approving the allocation of the 2021 profit

The Chairman proposed that the Meeting consider approving the allocation of the 2021 profit and delegated Mrs. Narumol Noi-am, the Senior Executive Vice President and Chief Financial Officer, to provide the Meeting with the information.

Mrs. Narumol Noi-am, the Senior Executive Vice President and Chief Financial Officer, proposed that the Meeting consider and approve the allocation of dividends from the 2021 operating results and retained earnings at the rate of THB 0.45 per share to 15,892,001,895 ordinary shares, for which the total dividend will be THB 7,151.4 million. The entire amount of the dividend shall be allocated from non-BOI profits, representing a dividend payout of approximately 90.1% of the net profit based on the

consolidated financial statements, which complies with the Company's dividend payment policy to pay a dividend of not less than 50% of the net profit based on the consolidated financial statements.

On 29 October 2021, the Company paid an interim dividend at the rate of THB 0.25 per share, totaling THB 3,973.0 million; therefore, the Company shall pay a final dividend of THB 0.20 per share, totaling THB 3,178.4 million. The Company has set the record date for the shareholders that are entitled to receive dividends on 10 March 2022 (Record Date), and the dividend payment is scheduled to be made on 29 April 2022. In addition, the Company is not required to allocate profit to a legal reserve, as the Company has the full legal reserve amount in compliance with the Articles of Association of the Company.

The Chairman then gave the shareholders an opportunity to ask questions or express opinions in relation to this agenda item. No shareholders asked questions or expressed opinions. The Chairman then asked the Meeting to cast votes on this agenda item. Miss Kessara Wongsekate, the Company Secretary, informed the Meeting that the resolution on this agenda item shall be passed by a majority vote of the shareholders attending the Meeting and casting their votes.

Resolution: The Meeting resolved to approve the allocation of the 2021 profit, by a majority vote of the shareholders attending the Meeting and casting their votes, as follows:

	Number of votes		Percentage
Approved	11,259,771,859	votes	100.00 %
Disapproved	0	votes	0.00%
Abstained	0	votes	-
Invalid ballots	0	votes	-

Agenda Item 4: To consider electing directors in replacement of those who retire by rotation

For this agenda item, as the Chairman was the interested person in the matter, he assigned Mr. Chuladej Yossundharakul, M.D., Vice Chairman of the Board of Directors, to be the Chairman of the Meeting instead.

Mr. Chuladej Yossundharakul, M.D., Vice Chairman of the Board of Directors, delegated Mr. Predee Daochai, the Chairman of the Nomination and Remuneration Committee, to provide the Meeting with the information in support of the consideration and appointment of directors in replacement of the directors who are due to retire by rotation.

Mr. Predee Daochai, the Chairman of the Nomination and Remuneration Committee, informed the Meeting that Article 17 of the Company's Articles of Association provides that one-third of the members of the Board of Directors shall retire from office by rotation at every annual general meeting. Currently, there were six directors due to retire by rotation, namely:

1. Professor Emeritus Santsiri Sornmani, M.D. Independent Director
2. Mr. Att Thongtang Director
3. Mr. Arsa Sarasin Independent Director
4. Mr. Chairat Panthuraamphorn, M.D. Director
5. Mr. Sripop Sarasas Director
6. Mr. Pradit Theekakul Director

Mr. Arsa Sarasin has expressed his wish not to be nominated for re-election.

Furthermore, the Company gave the shareholders an opportunity to nominate a person qualified for the position of director, who possesses no prohibited characteristics, to be elected as a director in accordance with the criteria posted on the Company's website between 1 December 2021 and 14 January 2022 and no shareholders nominated any person.

The Board of Directors, as proposed by the Nomination and Remuneration Committee (excluding interested directors), had taken into consideration several reasons and appropriateness, including the candidates' past performance as directors and members of subcommittees, as well as the composition, in terms of the variety of qualifications, knowledge, abilities, specializations, and work experience, of the Board of Directors, and was of the view that the directors being proposed as directors for another term at this time have suitable qualifications for the Company's business operations and shall be able to use their knowledge and abilities to provide suggestions which are most beneficial to the Company. This being the case, it was deemed appropriate to propose that the Meeting consider the matter and appoint the five directors who are due to retire by rotation, namely, 1. Professor Emeritus Santasiri Sornmani, M.D., 2. Mr. Att Thongtang, 3. Mr. Chairat Panthuraamphorn, M.D., 4. Mr. Sripop Sarasas, and 5. Mr. Pradit Teekakul, for another term, which shall decrease the total number of board members to 17.

The directors who have been nominated for appointment do not hold a directorship position in any other company which would be in conflict or competition with the Company.

The profiles, experience, periods of directorship, and the number of attendances at board and sub-committee meetings of the five former directors being nominated to preside as directors, are set out in Enclosure 1, and the criteria and guidelines on the nomination of directors are set out in Enclosure 3, all of which were delivered to all shareholders together with the notice of the Meeting.

Professor Emeritus Santasiri Sornmani, M.D., an independent director, who is nominated for re-election for another term is deemed independent, as per the definition of an Independent Director of the Company and in line with the eligibility criteria of the Capital Market Supervisory Board, being able to provide independent opinions free from executives influence, having never been an executive or service professional and not having business relationships of material significance with the Company or its subsidiaries. (The Company's definition of an Independent Director is set out in Enclosure 4, which was delivered to all shareholders together with the notice of the Meeting.)

However, as for the nomination of Professor Emeritus Santasiri Sornmani, M.D., who has been in the position for more than nine years, to be re-elected as an Independent Director for another term, the Board of Directors and the Nomination and Remuneration Committee viewed that, during his term of office, he has been able to express his opinions independently and in accordance with the relevant rules.

The Chairman then gave the shareholders an opportunity to ask questions or express opinions in relation to this agenda item. No shareholders asked questions or expressed opinions. The Chairman then asked the Meeting to cast votes on this agenda item to consider re-electing the five directors who are due to retire by rotation on an individual basis. Miss Kessara Wongsekate, the Company Secretary, informed the Meeting that the resolution on this agenda item shall be passed by a majority vote of the shareholders attending the Meeting and casting their votes. The Company will collect all ballot cards, but the ballot cards of those who disapproved and abstained for each director will be collected first. For those who

approved in this agenda item, the ballot cards should be kept and returned to the Company's staff at the same time after voting for the last director.

Resolution: After due consideration, the Meeting resolved to approve the reappointment of five of the directors who are due to retire by rotation, for them to hold office as directors for another term, as proposed, which shall decrease the total number of board members to 17. The votes were cast individually for each director, as follows:

4.1 Professor Emeritus Santasiri Sornmani, M.D. Independent Director

	Number of votes		Percentage
Approved	9,754,332,017	votes	86.63%
Disapproved	1,505,440,934	votes	13.37%
Abstained	0	votes	-
Invalid ballots	0	votes	-

4.2 Mr. Att Thongtang Director

	Number of votes		Percentage
Approved	11,088,237,897	votes	98.48%
Disapproved	171,494,514	votes	1.52%
Abstained	40,540	votes	-
Invalid ballots	0	votes	-

4.3 Mr. Chairat Panthuraamphorn, M.D. Director

	Number of votes		Percentage
Approved	11,002,526,487	votes	97.72%
Disapproved	257,246,464	votes	2.28%
Abstained	0	votes	-
Invalid ballots	0	votes	-

4.4 Mr. Sripop Sarasas Director

	Number of votes		Percentage
Approved	10,938,444,133	votes	97.15%
Disapproved	321,328,818	votes	2.85%
Abstained	0	votes	-
Invalid ballots	0	votes	-

4.5 Mr. Pradit Theekakul Director

	Number of votes	Percentage
Approved	10,987,619,347 votes	97.58%
Disapproved	272,113,064 votes	2.42%
Abstained	40,540 votes	-
Invalid ballots	0 votes	-

In this regard, after the considering and approving the appointment of directors to replace those who have retired by rotation has ended, Mr. Chuladej Yossundharakul, M.D., Vice Chairman of the Board of Directors, assigned Professor Emeritus Santasiri Sornmani, M.D., to be the Chairman for the next agenda item.

Agenda Item 5: To consider approving the directors' remuneration

The Chairman delegated Mr. Predee Daochai, the Chairman of the Nomination and Reuneration Committee, to inform the Meeting of the details in support of the consideration of this agenda item.

Mr. Predee Daochai, the Chairman of the Nomination and Remuneration Committee, informed the Meeting that the Nomination and Remuneration Committee had thoroughly considered and reviewed the directors' remuneration by taking into account the economic situation, the revenue and profit growth of the Company, and concordance with businesses of the same size, as well as the duties and responsibilities of directors.

In this regard, the Board of Directors, as proposed by the Nomination and Remuneration Committee, deemed it appropriate to propose that the Meeting consider and approve the directors' remuneration as set out below:

1. Remuneration of the Company's directors

The Board of Directors and the Nomination and Remuneration Committee are of the opinion that the proposed criteria for calculating the director's remuneration at the rate of 0.1 percent of total revenue according to the consolidated financial statements of the previous year remains appropriate. Therefore, it is appropriate to propose to maintain the criteria for calculating the director's remuneration including meeting allowances and medical expenses at the same rate as the previous year as follows:

(Unit: THB)

Details	Proposed to 2022 AGM	2021 AGM	2020 AGM
1.1 Directors' remuneration (total) to be allocated among the board members themselves	75.7 million (0.1% of total revenue of the year 2021)	50.0 million ⁽¹⁾	64.05 million ⁽¹⁾

Details	Proposed to 2022 AGM	2021 AGM	2020 AGM
1.2 Meeting allowances			
- Chairman	75,000 per meeting	75,000 per meeting	75,000 per meeting
- Directors (each)	50,000 per meeting	50,000 per meeting	50,000 per meeting
1.3 Medical Expenses (For outside directors who are not executives or employees under employment contracts with the Company and/or its affiliates, and for treatment at Bangkok Hospital and affiliated hospitals only) ⁽²⁾	3 million per person per year (from the 2022 AGM to the next AGM)	3 million per person per year (from the 2021 AGM to the next AGM)	3 million per person per year (from the 2020 AGM to the next AGM)

Remarks:

- (1) In 2020 and 2021, due to the COVID-19 pandemic, the Board of Directors decided to reduce the directors' remuneration by 30% from the amount according to the directors' remuneration guideline, which resulted in the directors' remuneration of THB 64.05 million for the year 2020 and THB 50.0 million for the year 2021. (The directors' remuneration for 2020 and 2021 originally calculated according to the guideline should be THB 91.5 million and THB 71.4 million, respectively).
- (2) As of 12 April 2022, there are 9 outside directors (excluding the director who has expressed the wish not to be nominated for re-election) who are entitled to the medical expenses according to 1.3, namely, 1. Professor Emeritus Santasiri Sornmani, M.D., 2. Mr. Chavalit Sethameteekul, 3. Mr. Weerawong Chittmittrapap, 4. Mr. Kan Trakulhoon, 5. Mr. Thongchai Jira-alongkorn, 6. Mr. Puttipong Prasarttong-Osoth, 7. Mr. Subhak Siwaraksa, Ph.D. 8. Mr. Veerathai Santiprabhob, Ph.D., and 9. Mr. Predee Daochai.

2. Remuneration of the sub-committees

Remuneration of the sub-committees is proposed for approval in the form of meeting allowances at the same rate as the previous year, as set out below:

(Unit: THB)

Subcommittee	Proposed to 2022 AGM	2021 AGM	2020 AGM
2.1 Audit Committee			
Chairman	105,000 per meeting	105,000 per meeting	105,000 per meeting
Members (each)	70,000 per meeting	70,000 per meeting	70,000 per meeting

Subcommittee	Proposed to 2022 AGM	2021 AGM	2020 AGM
2.2 Executive Committee			
Chairman	90,000 per meeting	90,000 per meeting	90,000 per meeting
Members (each)	60,000 per meeting	60,000 per meeting	60,000 per meeting
2.3 Nomination and Remuneration Committee			
Chairman	75,000 per meeting	75,000 per meeting	75,000 per meeting
Members (each)	50,000 per meeting	50,000 per meeting	50,000 per meeting
2.4 Risk Management Committee			
Chairman	75,000 per meeting	75,000 per meeting	75,000 per meeting
Members (each)	50,000 per meeting	50,000 per meeting	50,000 per meeting
2.5 Corporate Governance Committee			
Chairman	75,000 per meeting	75,000 per meeting	75,000 per meeting
Members (each)	50,000 per meeting	50,000 per meeting	50,000 per meeting

The Chairman gave the shareholders an opportunity to ask questions or express opinions relating to this agenda item. No shareholders asked questions or expressed opinions. The Chairman then asked the Meeting to cast votes on this agenda item. Miss Kessara Wongsekate, the Company Secretary, informed the Meeting that the resolution on this agenda item shall be passed by votes of no less than two-thirds of the total number of votes of the shareholders attending the Meeting.

Resolution: After due consideration, the Meeting resolved, by votes of no less than two-thirds of the total number of votes of the shareholders attending the Meeting, to approve the directors' remuneration, as proposed, in accordance with the following votes:

	Number of votes	Percentage
Approved	11,133,683,126 votes	98.88%
Disapproved	125,543,533 votes	1.12%
Abstained	240,100 votes	0.00%
Invalid ballots	0 votes	-

Agenda Item 6: To consider appointing the auditors for the year 2022 and fixing the audit fee

The Chairman proposed that the Meeting consider and approve the appointment of the auditors for the year 2022, and the fixing of the audit fee, and asked Mr. Chavalit Sethameteekul, the Chairman of the Audit Committee, to inform the Meeting of the details of the auditors.

Mr. Chavalit Sethameteekul, the Chairman of the Audit Committee, informed the Meeting that, as indicated in the information delivered to all shareholders along with the notice of the Meeting, the Audit Committee had selected the auditors of the Company based on the following criteria:

1. The knowledge, ability, and experience of the auditors;
2. The availability of personnel and the number of personnel available, as well as the team's experience and performance in the past;
3. The reasonableness of the proposed fee, as compared to the amount of work and the audit fees of other listed companies at the same level;
4. The independence of the auditors and their audit firm, as not being persons who have a relationship and/or conflict of interest with the Company, its subsidiaries, executives, and major shareholders, or related persons of the aforesaid persons; and
5. The quality control of the significant audit work of the audit firm that helps ensure the quality of audit work.

The Board of Directors deemed it appropriate to propose that the shareholder's meeting consider and approve the following auditors of EY Office Limited as the auditors of the Company for the year 2022:

List of auditors proposed for appointment in this Meeting	Certified Public Accountant No.	Year signing as an auditor
1. Mr. Wichart Lokatekrawee	No. 4451	2018 – 2021
2. Ms. Kamontip Lertwitworatop	No. 4377	2016 – 2017
3. Mr. Samran Taengcham	No. 8021	-

In addition, it was proposed to approve the audit fee for the year 2022, in an amount not exceeding THB 2,450,000, which is the same rate as the previous year, as set out below:

(unit: THB)

Audit Fee	2022	2021	2020
Quarterly audit fee (for 3 quarters)	1,047,000	1,047,000	1,047,000
Annual audit fee	1,403,000	1,403,000	1,403,000
Total audit fee	2,450,000	2,450,000	2,450,000

Remark: The above audit fee does not include other service fees (non-audit fees).

In this regard, the proposed auditors, and EY Office Limited, are the auditors of the Company and all of its subsidiaries, have no relationship with, nor any interests in the Company, its subsidiaries, executives, and major shareholders, or related persons of the aforementioned parties. In addition, the auditors demonstrated independence in auditing and providing their professional opinions on the financial statements of the Company and its subsidiaries. The profiles and experience of the nominated auditors for 2022 are set out in Enclosure 5 of the notice of the Meeting that was sent to the shareholders.

The Chairman then gave the shareholders an opportunity to ask questions and express opinions related to this agenda item. No shareholders asked any questions or expressed any opinions. Therefore, the Chairman requested the Meeting to vote on this agenda item. Miss Kessara Wongsekate, the Company Secretary, informed the Meeting that the resolution on this agenda item shall be passed by a majority vote of the shareholders attending the Meeting and casting their votes.

Resolution: After due consideration, the Meeting resolved, by a majority vote of the shareholders attending the Meeting and casting their votes, to approve the appointment of Mr. Wichart Lokatekrawee, Certified Public Accountant No. 4451; and/or Ms. Kamontip Lertwitworatep, Certified Public Accountant No. 4377; and/or Mr. Samran Taengcham Certified Public Accountant No. 8021, of EY Office Limited, as the auditors of the Company for the year 2022, and to approve the audit fee at THB 2,450,000 (excluding non-audit fees), as proposed, in accordance with the following votes:

	Number of votes		Percentage
Approved	11,172,679,259	votes	99.23%
Disapproved	86,784,900	votes	0.77%
Abstained	2,600	votes	-
Invalid ballots	0	votes	-

Agenda Item 7: To consider other matters (if any)

The Chairman informed the Meeting that, as all agenda items indicated in the notice of the Meeting had been fully considered by the Meeting, the shareholders were to be given an opportunity to ask further questions and express further opinions. As no shareholders wished to ask any further questions or express any further opinions, the Chairman then declared the Meeting adjourned and expressed his appreciation to all shareholders for their participation and providing beneficial recommendations to the Company.

The Meeting was adjourned at 14:42.

Signed by **Professor Emeritus Santasiri Sornmani, M.D.**

(Professor Emeritus Santasiri Sornmani, M.D.)

Chairman of the Meeting

Signed by **Kessara Wongsekate**
(Miss Kessara Wongsekate)
Company Secretary